Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.45−0.16 (-26.87%)
Close on Nov 16, 2026Market cap $259.49KP/E –Yield –
Virax Biolabs total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Virax Biolabs
Virax Biolabs has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?